Dupont Jakob 4
4 · Pyxis Oncology, Inc. · Filed Mar 25, 2026
Research Summary
AI-generated summary of this filing
Pyxis Oncology Director Jakob Dupont Receives 45,867-Share Award
What Happened Jakob Dupont, a director of Pyxis Oncology (PYXS), received a grant/award on 2026-03-24 covering 45,867 shares (reported as a derivative acquisition at $0.00). The filing shows a grant (code A) with no immediate cash value reported; the award will vest 100% on the first anniversary of the grant date, subject to continued service.
Key Details
- Transaction date: 2026-03-24; Form 4 filed: 2026-03-25 (timely filing).
- Transaction type: Grant/award of a derivative instrument (reported as 45,867 shares @ $0.00).
- Vesting: 100% vests on the first anniversary of the grant (footnote).
- Shares owned after transaction: Not specified in the provided excerpt.
- Other notes: No 10b5-1, tax-withholding, or cashless-exercise details were listed in the provided data.
Context This was a compensation-related derivative grant (likely stock options or similar) that does not represent an immediate purchase or sale of shares. Because the award vests in one year and is subject to continued service, it is not immediately realizable and should be viewed as part of ongoing executive/director compensation rather than a direct market signal.
Insider Transaction Report
- Award
Stock Option (Right to Buy)
[F1]2026-03-24+45,867→ 45,867 totalExercise: $1.36Exp: 2036-03-24→ Common Stock (45,867 underlying)
Footnotes (1)
- [F1]The shares subject to this option will vest 100% on the first anniversary of the grant date, subject to the reporting person's continued service through the applicable vesting date.